help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Parker, K. L.
Right arrow Articles by Lee, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parker, K. L.
Right arrow Articles by Lee, P. A.

Journal of Clinical Endocrinology & Metabolism, Vol 73, 50-52, Copyright © 1991 by Endocrine Society

ARTICLES

Depot leuprolide acetate dosage for sexual precocity

KL Parker, RG Baens-Bailon and PA Lee
Children's Hospital of Pittsburgh, Pennsylvania 15213.

Twenty-one children with early puberty have been evaluated to determine adequate dosage of depot leuprolide acetate. The minimal dosage of depot leuprolide acetate required, using intervals of 1.5 mg or less when given every 28 days, was determined. This dosage, as determined by suppression of gonadotropin responses to GnRH stimulation, was 4.14 +/- 1.33 mg (mean +/- SD) and 0.15 +/- 0.07 mg/kg.28 days. The dosage correlates with bone age and pubertal stage and is larger among patients with more advanced puberty. Five patients required a larger dosage from 5-10 months after initial suppression. Therefore, to monitor suppression, GnRH testing should be repeated at least at 6- month intervals. Samples 20 and 40 min after GnRH stimulation are sufficient to indicate adequacy of treatment, so an abbreviated test could be used.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
A. Badaru, D. M. Wilson, L. K. Bachrach, P. Fechner, L. M. Gandrud, E. Durham, K. Wintergerst, C. Chi, K. O. Klein, and E. K. Neely
Sequential Comparisons of One-Month and Three-Month Depot Leuprolide Regimens in Central Precocious Puberty
J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1862 - 1867.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
J.-C. Carel, J. Blumberg, C. Seymour, C. Adamsbaum, N. Lahlou, and for the Triptorelin 3-month CPP Study Group
Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty
Eur. J. Endocrinol., January 1, 2006; 154(1): 119 - 124.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
V. N. Brito, A. C. Latronico, I. J. P. Arnhold, and B. B. Mendonca
A Single Luteinizing Hormone Determination 2 Hours after Depot Leuprolide Is Useful for Therapy Monitoring of Gonadotropin-Dependent Precocious Puberty in Girls
J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4338 - 4342.
[Abstract] [Full Text] [PDF]

Home page
 CLIN PEDIATRHome page
M. Maniati-Christidi, S. Livadas, A. Voutetakis, G. Tolis, and C. Dacou-Voutetakis
Human Growth Hormone and Gonadotropin Releasing Hormone Analog Combination Therapy Increases Predicted Height in Short Normal Girls
Clinical Pediatrics, January 1, 2003; 42(1): 59 - 65.
[Abstract] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J.-C. Carel, N. Lahlou, O. Jaramillo, V. Montauban, C. Teinturier, M. Colle, C. Lucas, and J. L. Chaussain
Treatment of Central Precocious Puberty by Subcutaneous Injections of Leuprorelin 3-Month Depot (11.25 mg)
J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4111 - 4116.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
V. Mericq, H. Gajardo, M. Eggers, A. Avila, and F. Cassorla
Effects of Treatment with GH Alone or in Combination with LHRH Analog on Bone Mineral Density in Pubertal GH-Deficient Patients
J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 84 - 89.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. V. MERICQ, M. EGGERS, A. AVILA, G. B. CUTLER Jr., and F. CASSORLA
Near Final Height in Pubertal Growth Hormone (GH)-Deficient Patients Treated with GH Alone or in Combination with Luteinizing Hormone-Releasing Hormone Analog: Results of a Prospective, Randomized Trial
J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 569 - 573.
[Abstract] [Full Text]

Home page
 Arch. Dis. Child.Home page
V. N de Brito, A. C Latronico, I. J P Arnhold, L. S S Lo, S. Domenice, M. C C Albano, M. C B V Fragoso, and B. B Mendonca
Treatment of gonadotropin dependent precocious puberty due to hypothalamic hamartoma with gonadotropin releasing hormone agonist depot
Arch. Dis. Child., March 1, 1999; 80(3): 231 - 234.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. Cassorla, V. Mericq, M. Eggers, A. Avila, C. Garcia, A. Fuentes, S. R. Rose, and G. B. Cutler Jr.
Effects of Luteinizing Hormone-Releasing Hormone Analog-Induced Pubertal Delay in Growth Hormone (GH)-Deficient Children Treated with GH: Preliminary Results
J. Clin. Endocrinol. Metab., December 1, 1997; 82(12): 3989 - 3992.
[Abstract] [Full Text] [PDF]

Home page
 CLIN PEDIATRHome page
P. A. Lee
Advances in the Management of Precocious Puberty
Clinical Pediatrics, January 1, 1994; 33(1): 54 - 61.
[PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1991 by The Endocrine Society